Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies

Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans in...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutilier, Ava J., Huang, Lina, Elsawa, Sherine F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569492/
https://www.ncbi.nlm.nih.gov/pubmed/36232447
http://dx.doi.org/10.3390/ijms231911145
_version_ 1784809867187322880
author Boutilier, Ava J.
Huang, Lina
Elsawa, Sherine F.
author_facet Boutilier, Ava J.
Huang, Lina
Elsawa, Sherine F.
author_sort Boutilier, Ava J.
collection PubMed
description Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.
format Online
Article
Text
id pubmed-9569492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95694922022-10-17 Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies Boutilier, Ava J. Huang, Lina Elsawa, Sherine F. Int J Mol Sci Review Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas. MDPI 2022-09-22 /pmc/articles/PMC9569492/ /pubmed/36232447 http://dx.doi.org/10.3390/ijms231911145 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Boutilier, Ava J.
Huang, Lina
Elsawa, Sherine F.
Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
title Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
title_full Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
title_fullStr Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
title_full_unstemmed Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
title_short Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
title_sort waldenström macroglobulinemia: mechanisms of disease progression and current therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569492/
https://www.ncbi.nlm.nih.gov/pubmed/36232447
http://dx.doi.org/10.3390/ijms231911145
work_keys_str_mv AT boutilieravaj waldenstrommacroglobulinemiamechanismsofdiseaseprogressionandcurrenttherapies
AT huanglina waldenstrommacroglobulinemiamechanismsofdiseaseprogressionandcurrenttherapies
AT elsawasherinef waldenstrommacroglobulinemiamechanismsofdiseaseprogressionandcurrenttherapies

Ejemplares similares